6-K 1 a18-17124_16k.htm 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 6-K

 


 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July 11, 2018

 


 

Commission File Number: 001 - 38178

 


 

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 


 

Smedeland 36
2600 Glostrup (Copenhagen)
Denmark

(Address of principal executive offices)

 


 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x            Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated July 11, 2018, announcing that Zealand Pharma has received information from Van Herk Investments B.V., that they have increased their investment in Zealand Pharma to above 5% of Zealand’s outstanding shares. Their holding following the increase amounts to 6.38% or 1,962,535 shares.

 

 

 



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Zealand Pharma A/S

 

 

 

 

By:

/s/ Mats Blom

 

 

Name:

Mats Blom

 

 

Title:

Chief Financial Officer

 

Date: July 11, 2018

 

2



 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Company announcement dated July 11, 2018

 

3